The Chemical Genomics Centre
The Chemical Genomics Centre is an initiative of the Max Planck Society in cooperation with Merck, AstraZeneca, Boehringer Ingelheim, Bayer HealthCare and Bayer CropScience. It stands for high quality research in the area of Chemical Genomics and strong collaborations between industry and Max Planck research.
Based on the experience gained in the first funding period of the CGC (2005-2010) the concept of the second funding period of the CGC (2012-2017) was developed further and evolved to guarantee efficient research and collaboration among the participating groups. The scientific focus will remain to be on the chemical-biological analysis of biological phenomena through the use of small molecules.